Cargando…

Renoprotective Effect of the Combination of Renin-angiotensin System Inhibitor and Calcium Channel Blocker in Patients with Hypertension and Chronic Kidney Disease

BACKGROUND: Renin-angiotensin system inhibitor and calcium channel blocker (CCB) are widely used in controlling blood pressure (BP) in patients with chronic kidney disease (CKD). We carried out a meta-analysis to compare the renoprotective effect of the combination of angiotensin-converting enzyme i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Rong-Shuang, Cheng, Yi-Ming, Zeng, Xiao-Xi, Kim, Sehee, Fu, Ping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2016
Materias:	Meta Analysis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4804438/ https://www.ncbi.nlm.nih.gov/pubmed/26904991 http://dx.doi.org/10.4103/0366-6999.176987

Ejemplares similares

Renoprotective effects of renin–angiotensin system inhibitor combined with calcium channel blocker or diuretic in hypertensive patients: A PRISMA-compliant meta-analysis
por: Cheng, Yiming, et al.
Publicado: (2016)

Renin–angiotensin–aldosterone system inhibitors and the risk of mortality in patients with hypertension hospitalised for COVID-19: systematic review and meta-analysis
por: Ssentongo, Anna E, et al.
Publicado: (2020)

Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers and cancer risk: an updated meta-analysis of observational studies
por: Shin, Kayeong, et al.
Publicado: (2022)

Renin–angiotensin–aldosterone system blockers and region-specific variations in COVID-19 outcomes: findings from a systematic review and meta-analysis
por: Kaur, Upinder, et al.
Publicado: (2021)

Effects of adding tripterygium glycosides to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on albuminuria in patients with diabetic nephropathy
por: Fang, Jin-Ying, et al.
Publicado: (2020)

Valsartan vs. other angiotensin II receptor blockers in the treatment of hypertension: a meta-analytical approach
por: Nixon, R M, et al.
Publicado: (2009)

The effect of renin–angiotensin–aldosterone system inhibitors in patients with hypertension and COVID-19: A meta-analysis of randomized controlled trials and propensity score-matched studies
por: Zhang, Kai, et al.
Publicado: (2022)

Renin-angiotensin system inhibitors and risk of fractures: a prospective cohort study and meta-analysis of published observational cohort studies
por: Kunutsor, Setor K., et al.
Publicado: (2017)

Fixed-Dose Combinations of Renin–Angiotensin System Inhibitors and Calcium Channel Blockers in the Treatment of Hypertension: A Comparison of Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors
por: Hsiao, Fu-Chih, et al.
Publicado: (2015)

An umbrella review and meta‐analysis of renin–angiotensin system drugs use and COVID‐19 outcomes
por: Kurdi, Amanj, et al.
Publicado: (2022)

Effect of preoperative renin-angiotensin system blockade on vasoplegia after cardiac surgery: A systematic review with meta-analysis
por: Noubiap, Jean Jacques, et al.
Publicado: (2022)

Reno-protective effects of renin–angiotensin system blockade in type 2 diabetic patients: a systematic review and network meta-analysis
por: Vejakama, P., et al.
Publicado: (2011)

Account for Clinical Heterogeneity in Assessment of Catheter-based Renal Denervation among Resistant Hypertension Patients: Subgroup Meta-analysis
por: Chen, Xiao-Han, et al.
Publicado: (2017)

Clinical application of angiotensin receptor blockers in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis
por: Li, Yating, et al.
Publicado: (2018)

Diagnostic value of aldosterone to renin ratio calculated by plasma renin activity or plasma renin concentration in primary aldosteronism: a meta-analysis
por: Liu, Zhenjie, et al.
Publicado: (2022)

Renin‐Angiotensin System Inhibitors in Patients With COVID‐19: A Meta‐Analysis of Randomized Controlled Trials Led by the International Society of Hypertension
por: Gnanenthiran, Sonali R., et al.
Publicado: (2022)

Influence of angiotensin converting enzyme inhibitors/angiotensin receptor blockers on the risk of all‐cause mortality and other clinical outcomes in patients with confirmed COVID‐19: A systemic review and meta‐analysis
por: Jia, Na, et al.
Publicado: (2021)

Effects of L-/N-Type Calcium Channel Blockers on Angiotensin II–Renin Feedback in Hypertensive Patients
por: Kawabata, Yutaka, et al.
Publicado: (2020)

Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors in COVID-19: Meta-analysis/Meta-regression Adjusted for Confounding Factors
por: Lee, Terry, et al.
Publicado: (2021)

Renoprotective effect of nicorandil in patients undergoing percutaneous coronary intervention: a meta-analysis of 4 randomized controlled trials
por: Wang, Xiaobing, et al.
Publicado: (2018)

Calcium channel blockers, angiotensin receptor blockers, and angiotensin-converting enzyme inhibitors: Effectiveness in combination with diuretics or β-blockers for treating hypertension
por: Bisognano, John D, et al.
Publicado: (2007)

Addition of a renin-angiotensin-aldosterone system inhibitor to a calcium channel blocker ameliorates arterial stiffness
por: Kiuchi, Shunsuke, et al.
Publicado: (2015)

Calcium channel blocker monotherapy versus combination with renin-angiotensin system inhibitors on the development of new-onset diabetes mellitus in hypertensive Korean patients
por: Kim, Yong Hoon, et al.
Publicado: (2019)

Development and Validation of a Medication Selection Model Under Clinical Application of Renin-Angiotensin Inhibitor Combined with Calcium Channel Blocker for Hypertension Patients
por: Hong, Dongsheng, et al.
Publicado: (2020)

High-dose versus low-dose angiotensin converting enzyme inhibitors in heart failure: systematic review and meta-analysis
por: Migliavaca, Celina Borges, et al.
Publicado: (2020)

Efficacy of Sodium-Glucose Cotransporter-2 inhibitors in heart failure patients treated with dual angiotensin receptor blocker-neprilysin inhibitor: An updated meta-analysis
por: Yamani, Naser, et al.
Publicado: (2021)

A comparison of efficacy and safety of potassium‐competitive acid blocker and proton pump inhibitor in gastric acid‐related diseases: A systematic review and meta‐analysis
por: Simadibrata, Daniel Martin, et al.
Publicado: (2022)

Effect of sodium-glucose cotransporter-2 inhibitors on patients with essential hypertension and pre-hypertension: a meta-analysis
por: Ren, Bangjiaxin, et al.
Publicado: (2022)

Retrospective clinical study of renin-angiotensin system blockers in lung cancer patients with hypertension
por: Wei, Jie, et al.
Publicado: (2019)

Hypertension and renin-angiotensin system blockers are not associated with expression of angiotensin-converting enzyme 2 (ACE2) in the kidney
por: Jiang, Xiao, et al.
Publicado: (2020)

Renin‐Angiotensin Aldosterone System Inhibitors and COVID‐19: A Systematic Review and Meta‐Analysis Revealing Critical Bias Across a Body of Observational Research
por: Loader, Jordan, et al.
Publicado: (2022)

Efficacy and safety of sacubitril/valsartan in heart failure compared to renin–angiotensin–aldosterone system inhibitors: a systematic review and meta-analysis of randomised controlled trials
por: Hernandez, Adrian V., et al.
Publicado: (2023)

Ethnic differences in the association between angiotensin-converting enzyme gene insertion/deletion polymorphism and peripheral vascular disease: A meta-analysis
por: Han, Chao, et al.
Publicado: (2017)

Pooled analysis of the efficacy and safety of adjunctive alpha-blocker therapy before ureteroscopy in the management of ureteral stones
por: Tan, Hailin, et al.
Publicado: (2020)

Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers
por: Danser, A.H. Jan, et al.
Publicado: (2020)

Intra-abdominal hypertension and increased acute kidney injury risk: a systematic review and meta-analysis
por: Sun, Jing, et al.
Publicado: (2021)

Proton pump inhibitors and adverse effects in kidney transplant recipients: A meta-analysis
por: Boonpheng, Boonphiphop, et al.
Publicado: (2019)

A meta-analysis of the vascular-related safety profile and efficacy of α-adrenergic blockers for symptoms related to benign prostatic hyperplasia
por: Nickel, J C, et al.
Publicado: (2008)

Comparison of the cardioprotective and renoprotective effects of the L/N-type calcium channel blocker, cilnidipine, in adriamycin-treated spontaneously-hypertensive rats
por: Aritomi, Shizuka, et al.
Publicado: (2015)

Renin-angiotensin system inhibitors may have an advantage over calcium channel blockers in reducing proteinuria in gastric cancer patients receiving ramucirumab
por: Chiba, Takeshi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_odrhumc0sbj45lg1im7bsgdccs